1. Home
  2. SLN vs DSP Comparison

SLN vs DSP Comparison

Compare SLN & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

N/A

Current Price

$6.85

Market Cap

236.2M

Sector

Health Care

ML Signal

N/A

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

N/A

Current Price

$10.63

Market Cap

213.3M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SLN
DSP
Founded
1994
1999
Country
United Kingdom
United States
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
213.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SLN
DSP
Price
$6.85
$10.63
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$42.60
$18.06
AVG Volume (30 Days)
195.9K
161.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
160.87
EPS
N/A
N/A
Revenue
N/A
$289,235,000.00
Revenue This Year
N/A
$17.79
Revenue Next Year
N/A
$17.72
P/E Ratio
N/A
$93.83
Revenue Growth
N/A
29.74
52 Week Low
$1.97
$8.11
52 Week High
$7.78
$16.25

Technical Indicators

Market Signals
Indicator
SLN
DSP
Relative Strength Index (RSI) 71.58 54.34
Support Level $5.79 $8.34
Resistance Level $7.40 $10.73
Average True Range (ATR) 0.57 0.63
MACD 0.17 0.18
Stochastic Oscillator 90.33 76.63

Price Performance

Historical Comparison
SLN
DSP

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

Share on Social Networks: